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Background: Alpha-mannosidosis is caused by mutations in MAN2B1, leading to loss of lysosomal alpha-mannosidase
activity. Symptoms include intellectual disabilities, hearing impairment, motor function disturbances, facial coarsening
and musculoskeletal abnormalities.
Methods: To study the genotype-phenotype relationship for alpha-mannosidosis 66 patients were included. Based on
the predicted effect of the mutations and the subcellular localisation of mutant MAN2B1 in cultured cells, the patients
were divided into three subgroups.
Clinical and biochemical data were collected. Correlation analyses between each of the three subgroups of genotype/
subcellular localisation and the clinical and biochemical data were done to investigate the potential relationship
between genotype and phenotype in alpha-mannosidosis.
Statistical analyses were performed using the SPSS software. Analyses of covariance were performed to describe the
genotype-phenotype correlations. The phenotype parameters were modelled by the mutation group and age as a
covariate. P values of <0.05 were considered as statistically significant.
Results: Complete MAN2B1 genotypes were established for all patients. We found significantly higher scores in the
Leiter-R test, lower concentrations of CSF-oligosaccharides, higher point scores in the Bruininks-Oseretsky Test of Motor
Proficiency subtests (BOT-2); Upper limb coordination and Balance, and a higher FVC% in patients in subgroup 3,
harbouring at least one variant that allows localisation of the mutant MAN2B1 protein to the lysosomes compared to
subgrou 2 and/or subgroup 1 with no lysosomal localization of the mutant MAN2B1 protein.
Conclusion: Our results indicate a correlation between the MAN2B1 genotypes and the cognitive function, upper limb
coordination, balance, FVC% and the storage of oligosaccharides in CSF. This correlation depends on the subcellular
localisation of the mutant MAN2B1 protein.
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Alpha-mannosidosis is caused by pathogenic sequence
variants in MAN2B1, leading to loss of lysosomal alpha-
mannosidase activity. There is a broad phenotypic vari-
ation of manifestations, including intellectual disabilities,
hearing impairment, motor function disturbances, facial* Correspondence: line.gutte.borgwardt@regionh.dk
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deficiency [1, 2].
Together with other lysosomal exoglycosidases, alpha-
mannosidase cleaves sugar chains in a specific sequence
as a part of the glycoprotein degradation. After degrad-
ation, the components of the sugar chains are exported
from the lysosomes into the cytosol and reutilized [3].
Alpha-mannosidase deficiency causes a block in the
degradation of glycoproteins and thereby a progressive
lysosomal accumulation of soluble mannose-richss article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
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cellular function and apoptosis [4].
MAN2B1 comprises 24 exons and encodes a 1011
amino acid polypeptide [5]. The MAN2B1 polypeptide is
post-translationally modified in the endoplasmic reticulum
(ER), and during maturation and endosomal transport of
MAN2B1 to the lysosomes it is proteolytically cleaved into
three major polypeptides named “abc”, “d” and “e” of 70,
42 and 15 kDa, respectively [6]. Further specific, process-
ing of the 70 kDa subunit results in a total of five different
polypeptides [7].
Depending on the causative MAN2B1 mutation, mu-
tant MAN2B1 proteins have been detected in subcellular
compartments such as ER and lysosomes. For instance,
the protein can be folded incorrectly and arrested in the
ER, or it can be folded correctly and transported to the
lysosomes in an inactive form [8, 9].
A total of 127 MAN2B1 disease-associated mutations
have been reported (HGMD® Professional 2015.1 [10]. The
mutations are scattered throughout the coding region and
include missense mutations, nonsense mutations, frame-
shifting small insertions/duplications/deletions, in-frame
duplications, intronic splice site mutations and large dele-
tions. In a recent study, 96 alpha-mannosidosis-associated
mutations were reported in 130 unrelated patients from 30
countries [11]. Most of these mutations were private, but
three mutations, c.2248C>T (p.Arg750Trp), c.1830+1G>C
and c.2426 T>C (p.Leu809Pro), were relatively frequent,
and accounted for approximately 27 %, 5 % and 3 %, re-
spectively, of the disease alleles [11].
At present, there is no clear relationship between geno-
type and severity of the disease. The phenotypic variability
is high, even between siblings with identical genotypes [1,
12–15]. The molecular basis of alpha-mannosidase defi-
ciency and the phenotype has not previously been studied
systematically. However, results from two studies [11, 16]
indicated that there was no apparent correlation between
mutations and clinical phenotypes.
To study the genotype-phenotype correlation for
alpha-mannosidosis further, we performed mutation
analysis and investigated the potential relationship be-
tween the consequences of MAN2B1 mutations and the
results of motor function tests, cognitive test, and bio-
chemical tests, including alpha-mannosidase activity for
each of the 66 patients included in the study.
Materials and methods
Data presented in this paper are based on baseline data
from rhLAMAN-01; a natural history study of alpha-
mannosidosis and on baseline data from two randomised
clinical trials studying the efficacy and safety of enzyme
replacement therapy (ERT) with a recombinant human
alpha-mannosidase for patients with alpha-mannosidosis
(rhLAMAN-02 (EudraCT number: 2010-022084-36) [17,18]; and rhLAMAN-05 (EudraCT number: 2012-
000979-17) (unpublished data).
Patients
66 patients (57 unrelated) with clinically and enzymati-
cally confirmed alpha-mannosidosis, age 5-42, were in-
cluded. The majority of the patients were from Europe
(60), four originated from North Africa and two from
Pakistan. All patients included had the attenuated form
of alpha-mannosidosis (type II). 45 patients had previ-
ously been included in rhLAMAN-01 [18], and 35 pa-
tients in the rhLAMAN-02 or rhLAMAN-05 studies.
The clinical trials were performed in compliance with
the principles of the Declaration of Helsinki, ICH GCP
guidelines.
Mutation analysis of the MAN2B1 gene
Mutation analysis of the MAN2B1 gene and determin-
ation of the subcellular localisation of mutant MAN2B1
protein were performed as described in Riise Stensland
et al. [11]. Briefly, the 24 MAN2B1 exons, corresponding
exon-intron borders and parts of the 5’- and 3’- untrans-
lated regions were sequenced using the Sanger method.
When possible, parents were analysed for the mutations
found in their children in order to confirm their carrier
status and the allelic phase of the mutations. The soft-
ware Alamut Visual version 2.5-1 (Interactive Biosoft-
ware) was used to aid in the interpretiation of novel
variants. The effect of novel (potential) splice-site muta-
tions was studied on cDNA synthesized from RNA iso-
lated from peripheral blood cells. The effect of novel
missense mutations was studied by expression in cul-
tured cells as described in Riise Stensland et al. [11] and
slightly modified from Kuokkanen et al. [6]. Briefly, the
mutant MAN2B1 mutations were constructed by site-
directed mutagenesis of the WT MAN2B1 cDNA inserted
into the pcDNA3.1- vector and expressed in COS-7 cells
and/or HeLa cells. The mutant MAN2B1 protein variants
were assayed for MAN2B1 activity and the subcellular
processing was determined by western blot using rabbit
anti-recombinant human MAN2B1 antibodies. For sub-
cellular localisation, HeLa-cells were grown in 8-well
micro-slide chambers (Ibidi, Germany), fixated in ice-cold
methanol, blocked in PBS with 0.5 % BSA and stained
using rabbit anti-denatured bovine MAN2B1, mouse anti-
LAMP1 and mouse anti-PDI (primary antibodies) and
Alexa 488 goat anti-rabbit and Alexa 568 goat anti-mouse
as secondary antibodies. A confocal microscope (Zeiss
LSM780, Carl Zeiss Microscopy GmbH, Germany) was
used to capture Z-stack images of the transfected cells.
Based on the results from the mutation analysis and
predicted (null mutations) or determination of subcellu-
lar MAN2B1 protein localisation, patients were divided
into three subgroups:
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cations). Subcellular localisation of the mutant
MAN2B1 proteins was not studied.
II. At least one missense mutation (or in-frame deletion/
duplication of 1-5 amino acids) with the MAN2B1
protein localised to the endoplasmic reticulum (ER)
(ie: ER/ER, ER/null).
III. At least one missense mutation (or in-frame
deletion/duplication of 1-5 amino acids) with the
MAN2B1 protein localised to the lysosomes (lyso)
(ie: lyso/lyso, lyso/ER, lyso/null).
Collection of clinical and biochemical data
RhLAMAN-01 data were collected at four European
centres. RhLAMAN-02 and rhLAMAN-05 data were
collected at one center. Clinical and biochemical data
were collected prospectively. Assessments, including six-
minutes-walk test (6-MWT), pulmonary function test,
alpha-mannosidase enzyme activity and audiometry
were made in all patients included in rhLAMAN-01,
rhLAMAN-02 and rhLAMAN-05 (n = 66). Assess-
ments, including Three-minutes-stair-climb-test (3-
MSCT), The Bruininks-Oseretsky Test of Motor Profi-
ciency (BOT-2), cognitive function test, Cerebral Spinal
Fluid (CSF)-oligosaccharides, S-oligosaccharides and
specific CSF-biomarkers (CSF-tau-protein (CSF-T-tau),
CSF-Glial Fibrillary Acidic protein (CSF-GFAp), CSF-
NeuroFilament Light protein (CSF-NFLp)) were made
only for patients included in rhLAMAN-02 and
rhLAMAN-05 (n = 35).
Biochemical assessments
Oligosaccharides
Lumbar puncture and blood sampling were performed
for the 35 patients participating in rhLAMAN-02 and
rhLAMAN-05 for measurement of CSF-oligosaccharides
and serum-oligosaccharides, respectively. Oligosaccha-
rides in CSF and serum were determined quantitatively
by electrospray tandem mass spectrometry. Assays were
performed at the Danish Technology Institute, Kolding,
Denmark.
CSF-biomarkers of neurodegeneration
Lumbar puncture was performed for the 35 patients
participating in rhLAMAN-02 and rhLAMAN-05 and
measurement of CSF biomarkers, T-tau, NFLp and
GFAp were done. Thirty four of 35 CSF-samples were
analysed. The total volume of CSF was seven ml. For
CSF biomarkers the CSF was frozen at -20 °C, for CSF
oligosaccharides at -80 °C.
CSF T-tau was measured using an ELISA assay
(INNOTEST hTau Ag, Innogenetics, Ghent, Belgium) [19].
CSF GFAP and CSF NFLp were measured using an in-
house developed sandwich ELISA [20, 21]. Determinationof levels of CSF biomarkers was performed at Sahlgrenska
Hospital, Göteborg, Sweden.
Alpha-mannosidase activity
Determination of alpha-mannosidase activity was done in
serum in rhLAMAN-01, and in plasma in rhLAMAN-02
and rhLAMAN-05. Both determinations were performed
as described by Masson and Lundblad [22].
To make the two methods comparable, enzyme activ-




The cognitive function has been investigated in another
study of ours [23]. Briefly, the Leiter International Per-
formance Scale-Revised (Leiter R) was used [24–26].
The test consists of two test batteries; Visual Function
and Reasoning battery and Memory and Attention bat-
tery. For each of the test batteries a measure of the overall
functioning level, a total equivalent age, is obtained. All 35
patients performed the Visual Function and Reasoning
battery, only 26, enrolled or screened for rhLAMAN-05,
performed the Memory and Attention battery.
Pulmonary function test
Pulmonary function test measuring the forced vital cap-
acity (FVC) (and percentage of predicted value, depending
on age, size and sex (FVC%), was performed in accordance
with American Thoracic Society (ATS)-standards and The
European Respiratory Society Statements (ERS) [27].Motor function assessments
6MWT was performed in accordance with ATS-standards
[28]. 3MSCT is not a standardised test, but was performed
according to published guidelines [29–31]. BOT-2 is a
standardised and validated test measuring fine and gross
motor skills of children and adolescents [32].Audiometry
Unaided pure-tone audiometry at frequencies 0.25, 0.5,
1, 2 and 4 kHz was carried out in accordance with ISO
8253–1 [33].Statistical analysis
Statistical analyses were performed using the SPSS soft-
ware. Analyses of covariance were performed to describe
the genotype-phenotype correlations. The phenotype pa-
rameters were modelled by the mutation group and age
as a covariate. P values of <0.05 were considered as sta-
tistically significant.
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No formal sample size calculation was performed for
this study. The sample size is from a statistical point of
view a small number of persons, but it represents a
compromise between the limited number of persons
fulfilling the inclusion/exclusion criteria and the min-
imal amount of data which can support a possible
genotype-phenotype correlation.
Results
The diagnosis of alpha-mannosidosis was established in
all 66 patients (24 females and 42 males), age 5 to
42 years (mean 19.4), from 57 families based on defi-
ciency of acid alpha-mannosidase activity in leukocytes
or serum.
Mutation spectrum and functional analyses of novel
missense variants
Disease-associated MAN2B1 mutations were identified
in all patients. About half of the unrelated patients were
homozygous (28 of 57). In total we detected 56 disease-
associated variants, of which 11 were novel (see Tables 1
and 2 and Fig. 1). None of the novel mutations were
present in dbSNP (http://www.ncbi.nlm.nih.gov/pro-
jects/SNP/) but c.2885G>A p.(Arg962His) was present
in the large database of exome sequences ExAc (Exome
Aggregation Consortium (www. http://exac.broadinstitu-
te.org/)) with a frequency of 2,47e-05 (3 alleles out ofTable 1 Novel MAN2B1 variants detected in this study
cDNA label Location Predicted effect on p
Nonsense mutations/duplications/deletions
c.383G>A Exon 3 p.(Trp128Ter)
c.809dupA Exon 6 p.(Asp270GlufsTer54)
c.812_813dupTG Exon 6 p.(Leu272CysfsTer27)
c.1047_1048dupCC Exon 8 p.(His350ProfsTer15)
c.2675dupT Exon 22 p.(Arg893AlafsTer38)
c.2944_2947delCCGT Exon 24 p.(Pro982ThrfsTer50)
Splice site mutations
c.1230 + 5G>A1 Intron 9 p.?
c.2436 + 5G>A Intron 20 p.Glu786_Met812del
Missense mutations
c.304G>A Exon 3 p.(Asp102Asn)
c.458G>T Exon 4 p.(Gly153Val)
c.2885G>A5 Exon 22 p.(Arg962His)
Mutations were labelled following the most recent Human Genome Variation Socie
residues were numbered using the MAN2B1 reference sequence NM 000528.3. The
for cDNA reference numbering, with +1 as A of the initiation codon ATG. At the pro
three-letter code. Protein labels are in parentheses if the variant has not been studi
1Located on the same allele (in cis) as the known pathogenic missense variant c.224
2In lysates of transiently transfected COS-7 cells: No≤20 % of WT; Some = 20-30 % o
3In lysates of transiently transfected COS-7 cells and HeLa-cells
4In vivo localisation in transiently transfected HeLa-cells
5Variant of uncertain clinical significance121 374). For 43 patients parental sequencing data were
collected, for 7 patients only sequencing data from the
mother or the father were collected and for 16 patients
the parental samples were not available.
Mutations were scattered all over the gene and in-
cluded missense mutations (23, 3 novel), small duplica-
tions (9, 4 novel), nonsense mutations (8, 1 novel), splice
site mutations (8, 1 novel), small deletions (6, 1 novel),
one large deletion (intron 6-13) and one novel intronic
variant (c.1230+5G>A).
Based on cDNA analyses in blood, the variant c.2436
+5G>A in intron 20 caused skipping of exon 20 and de-
leted 81 nt from the transcript (r.2356_2436del81,
p.Glu786_Met812del27). The effect of c.1230+5G>A in
intron 9 was not clear from the cDNA analysis and re-
quires further analyses. It was thus classified as a variant
of unknown clinical significance (VUS). However, the
variant was detected in two Spanish sibs, and in this
family it was on the same allele (in cis) as the known
disease-causing variant c.2248C>T (p.Arg750Trp). All
nonsense mutations, frame-shifting small deletions/du-
plications, large truncations caused by splice site muta-
tions and the large deletion were considered null-alleles.
In total, 23 missense mutations were detected in our
patient cohort. Of these, 3 were novel; c.304G>A
(p.Asp102Asn), c.458G>T (p.Gly153Val) and c.2885G>A
(p.Arg962His). Based on transfection experiments in cell




ty (HGVS) guidelines (version 2.121101, www.hgvs.org/mutnomen). Mutant
systematic names are preceded by a “c.” following the HGVS recommendations
tein level, names are preceded by “p.”. Amino acids are listed according to the
ed on RNA or protein level
8C>T p.Arg750Trp
f WT; Yes≥30 % of WT
Table 2 MAN2B1 mutations and genotype/subcellular localisation subgroups for all patients
Allele 1 Allele 2 Localisation Genotype group10/
subcellular localisation
subgroups
Family number Label cDNA Label Protein Label cDNA Label Protein
1A1 c.164G>T p.(Cys55Phe) c.599A>T p.(His200Leu) Exon 2 / Exon 4 3
1B1 c.164G>T p.(Cys55Phe) c.599A>T p.(His200Leu) Exon 2 / Exon 4 3
2 c.231G>A p.(Trp77Ter) c.2398G>C p.(Gly800Arg) Exon 2 / Exon 20 2*
3 c.283G>C p.(Ala95Pro) c.283G>C p(.Ala95Pro) Exon 3 / Exon 3 2
4 c.283G>C p.(Ala95Pro) c.283G>C p.(Ala95Pro) Exon 3 / Exon 3 2
5 c.304G>A p.(Asp102Asn) c.2885G>A p.(Arg962His) Exon 3 / Exon 23 3
6 c. 338_348dup11 p.(Ile117ProfsTer44) c. 338_348dup11 p.(Ile117ProfsTer44) Exon 3 / Exon 3 1
7 c.383G>A p.(Trp128Ter) c.383G>A p.(Trp128Ter) Exon 3 / Exon 3 1*
8 c.418C>T p.(Arg140Ter) c.418C>T p.(Arg140Ter) Exon 3 / Exon 3 1
9A2 c.458G>T p.(Gly153Val) c.[1230+5G>A;c.2248C>T] p.[?; Arg750Trp] Exon 4 / Intron 9 3
9B2 c.458G>T p.(Gly153Va) l c.[1230+5G>A; c.2248C>T] 11 p.[?; Arg750Trp] Exon 4 / Intron 9 3
10 c.590C>G p.(Pro197Arg) c.2724G>A p.(Trp908Ter) Exon 4 / Exon 22 2*
11 c.598C>A p.(His200Asn) c.1548delT p.(Leu518TrpfsTer5) Exon 4 / Exon 13 3*
12 c.685C>T p.(Arg229Trp) c.2439_2444dup6 p.(His814_Arg815dup) Exon 5 / Exon 21 3*
13 c.783C>A p.(Tyr261Ter) c.783C>A p.(Tyr261Ter) Exon 6 / Exon 6 1
14 c.788C>T p.Pro263Leu c.2355G>A p.(Arg757MetfsTer6) Exon 6 / Exon 19 3
15 c.809dupA p.(Asp270GlufsTer54) c.2675dupT p.(Arg893AlafsTer38) Exon 6 / Exon 22 1
16 c.812_813dupTG p.(Leu272CysfsTer27) c.812_813dupTG p.(Leu272CysfsTer27) Exon 6 / Exon 6 1
17 c.909+731del6272 p.Gly304del245 c.953C>T p.Ser318Leu Intron 6-13 / Exon 7 3
18 c.1026+2 T>G p.[Val339_Ala341del;
p.Val339_Gln342del]
c.1830+1G>C p.Val549_Glu610del Intron 7 / Intron 14 2
19 c.1047_1048dupCC p.(His350ProfsTer15) c.2248C>T p.Arg750Trp Exon 8 / Exon 18 2
20A3 c.1055 T>C p.(Leu352Pro) c.1055 T>C p.(Leu352Pro) Exon 8 / Exon 8 2
20B3 c.1055 T>C p.(Leu352Pro) c.1055 T>C p.(Leu352Pro) Exon 8 / Exon 8 2
21 c.1152_1153dupCC p.(His385ProfsTer93) c.1831-2A>G p.His611GlyfsTer3 Exon 9 / Intron 14 1
22 c.1152_1153dupCC p.(His385ProfsTer93) c.1152_1153dupCC p.His385ProfsTer93 Exon 9 / Exon 9 1
23 c.1310-2A>G p.(?) c.2248C>T p.Arg750Trp Intron 10 / Exon 18 2
24 c.1333C>T p.(His445Tyr) c.1333C>T p.(His445Tyr) Exon 11 / Exon 11 2
25 c.1351G>T p.(Gly451Cys) c.[1501 T>A; 2849G>C] 11 p.([Cys501Ser; Arg950Pro]) Exon 11 / Exon 12 3
26A4 c.1358C>T p.(Ser453Phe) c.1358C>T p.(Ser453Phe) Exon 11 / Exon 11 2
26B4 c.1358C>T p.(Ser453Phe) c.1358C>T p.(Ser453Phe) Exon 11 / Exon 11 2















Table 2 MAN2B1 mutations and genotype/subcellular localisation subgroups for all patients (Continued)
27B5 c.1370 T>A p.(Val457Glu) c.2248C>T p.Arg750Trp xon 11 / Exon 18 3*
28A6 c.1383C>A p.(Tyr461Ter) c.2402dupG p.(Ser802GlnfsTer129) xon 11 / Exon 20 1*
28B6 c.1383C>A p.(Tyr461Ter) c.2402dupG p.(Ser802GlnfsTer129) xon 11 / Exon 20 1*
29 c.1388_1389delGC p.(Arg463ProfsTer53) c.2426 T>C p.Leu809Pro xon 11 / Exon 20 2*
30 c.1527+1G>C p.(?) c.1527+1G>C p.(?) ntron 12 / Intron 12 1*
31A7 c.1816delA p.Thr606ProfsTer18 c.1830+1G>C p.Val549_Glu610del xon 14 / Intron 14 1
31B7 c.1816delA p.Thr606ProfsTer18 c.1830+1G>C p.Val549_Glu610del xon 14 / Intron 14 1
32 c.1830+1G>A p.(?) c.2248C>T p.Arg750Trp ntron 14 / Exon 18 2
33 c.1830+1G>C p.Val549_Glu610del c.1830+1G>C p.Val549_Glu610del ntron 14 / Intron 14 1
34 c.1830+1G>C p.Val549_Glu610del c.2248C>T p.Arg750Trp ntron 14 / Exon 18 2
35 c.1830+1G>C p.Val549_Glu610del c.2426 T>C p.Leu809Pro ntron 14 / Exon 20 2
36 c.1830+1G>C p.Val549_Glu610del c.2248C>T p.Arg750Trp ntron 14 / Exon 18 2
37A8 c.1831-2A>G p.His611GlyfsTer3 c.1831-2A>G p.His611GlyfsTer3 ntron 14 / Intron 14 1
37B8 c.1831-2A>G p.His611GlyfsTer3 c.1831-2A>G p.His611GlyfsTer3 ntron 14 / Intron 14 1
38 c.2234C>G p.(Thr745Arg) c.2234C>G p.Thr745Arg xon 18 / Exon 18 3
39A9 c.2248C>T p.Arg750Trp c.2248C>T p.Arg750Trp xon 18 / Exon 18 2*
39B9 c.2248C>T p.Arg750Trp c.2248C>T p.Arg750Trp xon 18 / Exon 18 2*
40 c.2248C>T p.Arg750Trp c.2248C>T p.Arg750Trp xon 18 / Exon 18 2*
41 c.2248C>T p.Arg750Trp c.2248C>T p.Arg750Trp xon 18 / Exon 18 2*
42 c.2248C>T p.Arg750Trp c.2248C>T p.Arg750Trp xon 18 / Exon 18 2*
43 c.2248C>T p.Arg750Trp c.2248C>T p.Arg750Trp xon 18 / Exon 18 2*
44 c.2248C>T p.Arg750Trp c.2299C>T p.Gln767Ter xon 18 / Exon 19 2*
45 c.2248C>T p.Arg750Trp c.2248C>T p.Arg750Trp xon 18 / Exon 18 2
46 c.2248C>T p.Arg750Trp c.2248C>T p.Arg750Trp xon 18 / Exon 18 2*
47 c.2248C>T p.Arg750Trp c.2426 T>C p.Leu809Pro xon 18 / Exon 20 2*
48 c.2248C>T p.Arg750Trp c.2248C>T p.Arg750Trp xon 18 / Exon 18 2
49 c.2248C>T p.Arg750Trp c.2426 T>C p.Leu809Pro xon 18 / Exon 20 2
50 c.2248C>T p.Arg750Trp c.2251G>T p.(Glu751Ter) xon 18 / Exon 20 2*
51 c.2248C>T p.Arg750Trp c.2248C>T p.Arg750Trp xon 18 / Exon 18 2
52 c.2355G>A p.Arg757MetfsTer6 c.2355G>A p.(Arg757MetfsTer6) xon 19 / Exon 19 1
53 c.2398G>T p.(Gly800Trp) c.2944_2947delCCGT p.(Pro982ThrfsTer50) xon 20 / Exon 24 2














































Table 2 MAN2B1 mutations and genotype/subcellular localisation subgroups for all patients (Continued)
55 c.2724G>A p.(Trp908Ter) c.2724G>A p.(Trp908Ter) Exon 22 / Exon 22 1
56 c.2920dupA p.(Thr974AsnfsTer81) c.2920dupA p.(Thr974AsnfsTer81) Exon 23 / Exon 23 1*
57 c.2921_2922delCA p.(Thr974ArgfsTer80) c.2921_2922delCA p.(Thr974ArgfsTer80) Exon 23 / Exon 23 1
Mutations are labelled according to HGVS recommendations (http://www.hgvs.org/mutnomen/) using the MAN2B1 coding DNA reference sequence NM_000528.3, where position +1 corresponds to A in the first ATG
translation initiation codon. Novel mutations are in bold. Protein labels are in parentheses if the variant has not been studied on RNA or protein level.
1-9Sibship 1-9, 10Subgroup 1: Two null-mutations (nonsense, frameshift, large truncations), subgroup 2: At least one missense mutation (or in-frame deletion/duplication of 1-5 amino acids) with the MAN2B1 protein
localised to the endoplasmic reticulum (ER) (ie: ER/ER, ER/null), subgroup 3: At least one missense mutation (or in-frame deletion/duplication of 1-5 amino acids) with the MAN2B1 protein localised to the lysosomes
(lyso) (ie: lyso/lyso, lyso/ER, lyso/null)















Fig. 1 Schematic view of the localisation and type of mutations in the study cohort. Boxes represent exons (coding region in grey), lines
represent introns. Mutations are labelled according to HGVS recommendations (http://www.hgvs.org/mutnomen/). Deletions, duplications and
splice variants are described using the MAN2B1 coding DNA reference sequence NM_000528.3, where position +1 corresponds to A in the first
ATG translation initiation codon. Novel mutations are in bold. Variants of uncertain clinical significance are in italics. *Variant c.1230+5G>A was
detected in two siblings where it was in cis with c.2248C>T p.Arg750Trp; variants c.1501T>A p.Cys501Ser and c.2849G>C p.Arg950Pro were in cis
in one patient
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medium and localised to the lysosomes (Figs. 2 and 3).
MAN2B1 p.Arg962His showed considerable residual
activity indistinguishable from the activity observed for
common, non-pathogenic variants [7] and in some ex-
periments resembling the level of the WT, and was
processed correctly and localised to the lysosomes.
However, the intensity of the bands representing theFig. 2 Western blot showing the intracellular processing and
secretion of the novel MAN2B1 missense variants in transfected COS-7
cells. The relative intensity of the different peptides is different for the
wild-type enzyme and the missense variants. a. Overexpressed and
transported MAN2B1 proteins are also secreted into the cell media in
the full-length form. b. The WT was included as a positive control of
MAN2B1 processing/secretion, pcDNA3.1 was included as a negative
control of MAN2B1 expression (cells transfected with an empty vector)
and MAN2B1 p.Arg750Trp was included as a negative control of
MAN2B1 processing/secretion (accumulates in the ER)processed peptides (as seen on western blot) was weaker
for the variant as compared to the wild-type MAN2B1
(Figs. 2 and 3), and it was consequently classified as
a VUS.
Genotype-phenotype correlations
Although all the patients included in this study were
classified as having the attenuated – type II alpha-
mannosidosis, their clinical phenotypes demonstrated a
large degree of variability. On the basis of the mutation
analysis, and the predicted effect of the mutations, the
patients were divided into the genotype/subcellular lo-
calisation subgroups. The distribution of patients and
ages in the three genotype/subcellular localisation sub-
groups are shown in Table 3.
The correlation between the three genotype/subcellu-
lar localisation subgroups and CNS related clinical and
biochemical data are shown in Fig. 4, the correlation be-
tween the three genotype/subcellular localisation sub-
groups and the motor function test and FVC% are
shown in Fig. 5.
Beside the significant correlations demonstrated in
Table 4, correlations between the genotype/subcellular lo-
calisation subgroups, including pairwise comparison, and
S-oligosaccharides; CSF-biomarkers; alpha-mannosidase
activity (%); 6-MWT; 3-MSCT and audiometry were per-
formed. No significant correlations were found (S-oligo-
saccharides: p=0.76 (age p=0.86), CSF-GFAp: p=0.11 (age
p=0.94), CSF-T-tau: p=0.12 (age p=0.006), CSF-NFLp:
Fig. 3 (See legend on next page.)
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Fig. 3 Confocal fluorescent microscopy images showing the intracellular localisation of the novel MAN2B1 missense variants in transfected
HeLa-cells. The first column of images shows methanol-fixed transfected HeLa-cells stained for MAN2B1 (green), the second column shows the same
cells stained for the lysosomal marker LAMP1 (red) and the third column shows merged images with colocalized MAN2B1 and LAMP1 (yellow). a:
MAN2B1 p.Asp102Asn; b: MAN2B1 p.Gly153Val; c: MAN2B1 p.Arg962His; d: WT. The WT was included as a positive control of lysosomal localization
Borgwardt et al. Orphanet Journal of Rare Diseases  (2015) 10:70 Page 10 of 16p=0.46 (age p=0.18), alpha-mannosidase activity (%):
p=0.19 (age p=0.10), 6-MWT: p=0.102 (age p=0.01): 3-
MSCT: p=0.82 (age p=0.60), Bone conducted hearing loss:
p=0.90 (age p=0.001): Air conducted hearing loss: p=0.37
(age p=0.26). Because of the non-significant results, pair-
wise comparisons are not reported.
Discussion
Two main findings have been obtained in this first sys-
tematic study of the potential relationship between
genotype and phenotype in alpha-mannosidosis.
Firstly, by analysing 66 patients from 57 families, 56
disease-associated mutations were identified. Complete
MAN2B1 genotypes were established for all patients
included.
Forty five mutations were described previously and 11
were novel. In accordance with previous findings, the
mutations were scattered all over the MAN2B1 gene and
included most types of mutations. The most frequent
missense mutation, c.2248C>T (p.Arg750Trp), was de-
tected in 20 unrelated patients from 9 countries and
accounted in this study for 25.4 % of the disease alleles
in unrelated patients, which is in accordance with previ-
ous reports [11, 16].
Secondly, we found that genotypes, allowing mutant
MAN2B1 protein to enter the lysosomes, correlated posi-
tively with several clinical and biochemical parameters.
Based on the predicted severity of the genotypes and
subcellular localisation of the mutant MAN2B1 protein,
we classified our patients into three subgroups. We
hypothesised that patients from subgroups 1 and 2, either
with two null-mutations or production of incorrectly
folded MAN2B1 proteins were expected to have the most
severe phenotype. The patients in subgroup 3, with at leastTable 3 The distribution of patients in the three subgroups
Genotype/subcellular localisation subgroups N Age +/-SD, Mean (years
Subgroup 1 21 22.9 ± 11.6
Two null-mutations
(nonsense, frameshift, large truncation)
Subgroup 2 32 17.9 ± 7.6
Missense/in-frame dup/del localised
to the ER
Subgroup 3 13 17.4 ± 7.8
Missense/in-frame dup/del
localised to the lysosomes
Total 66 19.4 ± 9.3one variant that allows localisation of the mutant
MAN2B1 protein to the lysosomes, were hypothesised to
show the mildest clinical presentation. They were ex-
pected to produce MAN2B1 proteins which fold suffi-
ciently to reach the lysosomes and which potentially could
confer some residual MAN2B1 activity.
As hypothesised, patients from subgroup 3, harbouring
at least one variant that allows localisation of the mutant
MAN2B1 protein to the lysosomes, performed signifi-
cantly better and had less abnormal results in some of
the clinical tests and biochemical analyses, compared to
patients in subgroup 2 and/or subgroup 1. Thus, in pa-
tients from subgroup 3, we found a significantly higher
total equivalent age in the two batteries employed in the
cognitive test, a higher point score in two BOT-2 sub-
tests (Upper limb coordination and Balance), a higher
FVC% and lower concentrations of CSF-oligosaccharides
compared to the other groups.
Our findings indicate a correlation between genotype/
intercellular localisation and the impact on CNS, pul-
monary function and motor function. The genotype-
phenotype correlation concerning the CNS function, are
supported by a significant negative correlation between
level of CSF-oligosaccharides and level of cognitive func-
tion in the same cohort; the higher level of CSF-
oligosaccharides, and the lower a total equivalent age in
the Memory Screening (p = 0.039 (age: p = 0.136) [23].
The significantly better performance of subgroup 3 pa-
tients in BOT-2 subtests (Upper limb coordination and
Balance), may indicate a genotype-phenotype correlation
concerning balance and muscular coordination. Disabil-
ities in muscular coordination and balance are well
known and important clinical features [1, 34], which





Fig. 4 The correlation between the three genotype/subcellular localisation subgroups and CNS related clinical and biochemical data. The
correlation between the three genotype/subcellular localisation subgroups and serum-oligosaccharides, CSF-oligosaccharides, total equivalent age
for Visual Function and Reasoning battery and Total equivalent age for Memory and Attention battery. (CSF-oligosaccharides: H0 3 = 2: p = 0.001,
H0 3 = 1: p = 0.011, H0 2 = 1: p = 1.000, Serum-oligosaccharides: p = 0.76 (age p = 0.86) (Because of the non-significant results, pairwise comparisons
are not reported), Total equivalent age for Visual Function and Reasoning battery (H0 3 = 2: p = 0.02, H0 3 = 1: p = 0.215, H0 2 = 1: p = 0.836), Total
equivalent age for Memory and Attention battery (H0 3 = 2: p = 0.296, H0 3 = 1: p = 0.003, H0 2 = 1: p = 0.042)
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phenotype correlation concerning the 6-MWT was also
found, which might indicate a relationship between the
different genotype/subcellular localisation subgroups and
motor function in general.
Due to intellectual disabilities, correctly performed spir-
ometry has been a challenge for some alpha-mannosidosis
patients. Thus, the values given at spirometry may be in-
accurate for some of the patients [17, 18] and the relation-
ship between the FVC% and the different subgroups may
be uncertain.
No significant correlation between genotype/subcellular
localisation subgroups and lysosomal alpha-mannosidase
residual activity was found, though previous studies have
suggested that severity of clinical expression is related to
the degree of reduced enzyme activity in human alpha-
mannosidosis patients [35]. However, other studies are inaccordance with our results [7, 36]. It has been sug-
gested that the missing correlation might be due to
alpha-mannosidases from other cellular compartments
that confer residual activity at low pH. This may be
misinterpreted as residual lysosomal alpha-mannosidase
activity [16]. Moreover, mutant MAN2B1 proteins,
mislocalised to non-lysosomal compartments (and
thus incapable of lysosomal glycoprotein degradation),
may show some activity when released into serum
from leukocytes [7].
Measuring residual lysosomal alpha-mannosidase ac-
tivity is difficult. The values for alpha-mannosidase ac-
tivities are low in all patients; hence, even minor
potential sources of error may influence the results sig-
nificantly and obscure a genotype/phenotype correl-
ation. Development of more accurate methods is
necessary for final conclusions of a genotype-phenotype
Fig. 5 Correlation between the three genotype/subcellular localisation subgroups and the motor function test and FVC%. BOT-2 subtest: Balance:
H0 3 = 2: p = 0.033, H0 3 = 1: p = 0.06, H0 2 = 1: p = 1.000, BOT-2 subtest: Upper limb and coordination: H0 3 = 2: p = 0.047, H0 3 = 1: p = 0.713, H0
2 = 1: p = 0.773, FVC%: H0 3 = 2: p = 0.296, H0 3 = 1: p = 0.003, H0 2 = 1: p:0.042. 6-MWT (six-minutes-walk-test): p = 0.102 (age: p = 0.01), 3-MSCT
(three-minutes-stair-climb-test): p=0.82 (age p=0.60). Because of the non-significant results, pairwise comparisons are not reported
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Table 4 Correlations between the three genotype/subcellular localisation subgroups and biochemical and clinical test results
Analysis/clinical test N Subgr. 1, mean Subgr. 2, mean Subgr. 3, mean Min. Max. Total, mean SD p-value Pairwise comparison*
CSF-oligo (μmol/L) 35/35 11.5 ± 2.3 11.9 ± 3.2 7.1 ± 2.0 4.0 19 10.7 3.4 H0 3 = 2: p = 0.001, H0 3 = 1: p = 0.011
H0 2 = 1: p = 1.000
Cognitive test
(VR battery) (years)
35/35 5.8 ± 1.7 5.3 ± 1.5 7.0 ± 0.9 3.0 9.0 5.8 1.6 H0 3 = 2: p = 0.049, H0 3 = 1: p = 0.344,
H0 2 = 1: p = 1.000
Cognitive test
(Memory Screening) (y)
26/26 6.9 ± 1.9 5.4 ± 2.0 8.8 ± 1.2 2.3 10.2 6.5 2.3 H0 3 = 2: p = 0.02, H0 3 = 1: p = 0.215,
H0 2 = 1: p = 0.836
FVC% (%) 54/66* 62.3 ± 20.7 77.5 ± 19 % 90.7 ± 22.7 30 140 75.2 22.7 H0 3 = 2: p = 0.296, H0 3 = 1: p = 0.003,
H0 2 = 1: p = 0.042
BOT-2 (Coor.) (points) 35/35 16.3 ± 10.1 11.3 ± 10.8 22.5 ± 7.6 1 33 15 10.8 H0 3 = 2:p = 0.047, H0 3 = 1: p = 0.713
H0 2 = 1: p = 0.773
BOT-2 (Balance) (points) 35/35 7.6 ± 6.2 8.4 ± 6.1 14.8 ± 7.9 1 26 9.7 7.0 H0 3 = 2: p = 0.033, H0 3 = 1: p = 0.06,
H0 2 = 1:p = 1.00
Significant correlations between the three genotype/subcellular localisation subgroups and CSF-oligosaccharides (CSF-oligo), Cognitive test (VR battery) (=Total equivalent age for the Visual function and reasoning bat-
tery), Cognitive test (Memory Screening) (Total equivalent age for the Memory Screening), Forced Vital Capacity (FVC%), BOT-2 (Upper limb coordination) (Coor.) and BOT-2 (Balance)
N = number, min. =minimum, Max. = Maximum, SD = standard deviation, * H0 3 = 2/ H0 3 = 1/ H0 2 = 1: Refers to the null hypothesis (H0) for the comparison of subgroup 3 versus subgroup 2 / subgroup 3 versus
subgroup 1 / subgroup 2 versus subgroup 1. p < 0.05 rejects the H0















Borgwardt et al. Orphanet Journal of Rare Diseases  (2015) 10:70 Page 14 of 16correlation concerning residual lysosomal alpha-
mannosidase activity.
Previously, genotype-phenotype correlations in alpha-
mannosidosis have been investigated in two studies [11,
16]. Our findings are not in line with those of Berg et al.
[16] and Riise Stensland et al. [11], who found no appar-
ent genotype-phenotype correlation when investigating
the relationship between different types of mutations
and the clinical subtype classification in 23 and 130 pa-
tients, respectively. These studies classified the patients
into three phenotypic subgroups, type 1, type 2 and type
3, according to the severity of manifestations as sug-
gested by Malm and Nilssen [34, 37]. Both studies were
conducted at a time before proper clinical end-points
were established. A challenge using these three pheno-
typic subgroups is that most of the patients diagnosed
with alpha-mannosidosis are intermediate type 2 pa-
tients. In the study by Riise Stensland et al. [11], 106 of
130 patients were classified as type 2, and in Berg et al.
[16], the clinical data were not collected in a standar-
dised format, but 22 of 23 patients were described with
moderate clinical manifestations.
Our cohort has not been classified into the above three
phenotypic subtypes, since the disease manifestations
display a continuum of clinical severity, as documented
from our large cohort of alpha-mannosidosis patients
and newer literature [1]. Instead, individual results from
clinical and biochemical tests were used to investigate
the relationship with the three genotype/subcellular lo-
calisation subgroups, making a more detailed and pre-
cise evaluation possible.
Our data have been collected in a standardised man-
ner. For rhLAMAN-02 and rhLAMAN-05 the same
doctor/nurse/ physiotherapist etc. assisted the patients
when performing the tests. For the two previous studies
[11, 16], clinical information for most of the patients
was collected by the referring physicians, which could
possibly introduce dissimilarity in the reporting.
Our findings demonstrated that genotypes allowing
mutant MAN2B1 protein to enter the lysosomes, corre-
lated positively with several clinical and biochemical pa-
rameters, though further investigation of a larger cohort
will be necessary before such correlation can be used in
clinical practice for postnatal or prenatal prognostics.
Despite our findings challenges still remain.
One challenge is a phenotypic variation within sibships
with identical MAN2B1 mutations [12–15, 38]. Riise
Stensland et al. [11] described 16 sibships with alpha-
mannosidosis classified in phenotypic subgroups 1-3,
and one was discordant. Among our patients participat-
ing in rhLAMAN-02 or rhLAMAN-05, one of three sib-
ships presented with different degrees of disease
involvement, especially with regard to the cognitive
function, though both patients in this sibship belongedto the attenuated type 2. The most affected sibling in
this sibship was treated twice with protracted mechan-
ical ventilation during the first 1.5 years of life, due to
Respiratory Syncytial Virus and bacterial pneumonia,
which may have influenced the severity of the pheno-
type, including the cognitive function. Based on our and
Riise Stensland et al.’s findings, the phenotypic variation
between sibs might not be as frequent as previously re-
ported, and may be explained by environmental and/or
epigenetic factors.
Another challenge is the fact that some patients clinic-
ally characterised as less severely or moderately affected
are homozygous for null mutations [16]. A possible ex-
planation to this phenomenon is that other mannosidases
than lysosomal alpha-mannosidase, may contribute to sal-
vage pathways in the degradation of glycoproteins. Evi-
dence for a role of cytosolic alpha-mannosidase in the
subcellular degradation of oligosaccharides was provided
by Grard et al. [39, 40]. Hence, it is possible that allelic
heterogeneity among extra-lysosomal alpha-mannosidases
could influence the phenotypic expression of alpha-
mannosidosis.
In view of the above considerations, we believe that
the genotype is fundamental in determining the severity
of alpha-mannosidosis, but other factors, both genetic,
epigenetic and environmental, may contribute to the ob-
served clinical variation. As examples, occurrence of se-
vere infections (which is common in alpha-
mannosidosis), differences in education, motor and cog-
nitive stimulation may affect the phenotype.
Conclusion
In conclusion, this study is the first to investigate the
genotype-phenotype correlation in alpha-mannosidosis
by classifying the cohort into three genotypic/subcellular
localisation subgroups and investigating the correlation
between the subgroups and the individual results of clin-
ical and biochemical tests. Our data indicate a genotype-
phenotype relationship between the genotype/subcellular
localisation subgroups and the cognitive function, the
BOT-2 motoric test, FVC% and the storage of oligosac-
charides in CSF. Patients from subgroup 3, with at least
one mutation that allows localisation of the mutant
MAN2B1 protein to the lysosomes, performed signifi-
cantly better and had less abnormal results in some of
the clinical tests and biochemical analyses, compared to
patients in subgroup 2 and/or subgroup 1.
Further investigation of a larger cohort will be neces-
sary before such correlation can be used in clinical prac-
tice for postnatal or prenatal prognostics.
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